BackAltimmune Overview

Altimmune Current Cash

Latest current cash for ALT: $63M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$63.05M
↓ 65.57% YoYΔ $-120.06M vs prior year quarter

Peer trimmed avg / median

Loading

Altimmune Current Cash History

Loading

Altimmune vs. peers: Current Cash Comparison

Loading

Altimmune Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Altimmune (ALT) FAQ

As of the most recent data (June 2026), ALT shows a current cash of $63M. That compares with $180M in the prior-year period — down 65.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ALT's current cash is now $63M (was $180M) — a 65.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Altimmune is outperforming or lagging.

Tracking ALT's current cash over time shows whether Altimmune is scaling, shrinking, or reshaping that part of the business. The current reading is $63M That compares with $180M in the prior-year period — down 65.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Altimmune's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $63M) with ownership activity and broader fundamentals.

Altimmune's current cash is $63M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.